glp1.md Blog

From Ozempic to the newest dual-agonists — every GLP-1 drug on the market in 2026, what it treats, how much weight loss to expect, and how they compare head to head.

Compare GLP-1 receptor agonists head-to-head: weight loss results, side effects, cost, and which might work best for you.

Nausea, constipation, and fatigue are common GLP-1 side effects. Most resolve with time. Here's what's normal and what needs medical attention.

GLP-1 drugs don't just kill your appetite. Here's what's actually happening in your body — the gut hormones, brain signals, and metabolic shifts explained without the jargon.

GLP-1 medications cost $1,000+/month without insurance. Here's how to navigate coverage, savings programs, and alternatives.

GLP-1 insurance coverage varies wildly by plan type, state, and diagnosis. Here's how to navigate the system and maximize your chances.

Exercise while on GLP-1 medications preserves muscle mass, improves metabolic health, and may help maintain results long-term.

Complete list of every GLP-1 drug available in 2026, from Ozempic to Mounjaro. Dosing, FDA approvals, costs, and how they compare—all in one guide.

Every GLP-1 side effect explained—from common nausea to rare risks like pancreatitis. What to expect, when to worry, and how to manage them.

How GLP-1 drugs like Ozempic and Mounjaro actually work in your body. The science of appetite, insulin, and weight loss—explained without jargon.

In the SURMOUNT-1 DXA substudy, about 25% of the weight lost on tirzepatide was lean mass — the same share as placebo. Here is what the research shows about muscle on GLP-1 drugs and what protects it.

Clinical trials show people regain about two-thirds of lost weight within a year of stopping semaglutide or tirzepatide. Here is what the research shows, and what helps people keep weight off.

GLP-1 drugs were designed for diabetes and weight loss. Then clinical trials revealed something unexpected — they're protecting hearts too. Here's what the research shows.

The 2023 advice was to hold weekly GLP-1 drugs for a week before surgery. The 2024 multisociety guidance reversed it for most patients. Here is what changed, and which risk factors still trigger a liquid diet.

The shortage that made compounded semaglutide legal ended in February 2025, and the FDA has logged 990 adverse event reports for compounded versions. Here is where the law stands and what the safety data shows.

FDA labels for Ozempic, Wegovy, Mounjaro and Zepbound do not ban alcohol. Real risks: low blood sugar with insulin, worse nausea, dehydration and pancreatitis.

Semaglutide weight loss flattened near week 60 in STEP 5 and held at 15%. Tirzepatide slows after week 36. How to tell a true plateau from a fixable one.

Food noise means intrusive, repetitive thoughts about food. Here is how researchers measure it, and what GLP-1 trial data shows about quieting it.

FDA labels rule out GLP-1 drugs for people with a personal or family history of medullary thyroid cancer, MEN 2, or a prior serious allergic reaction. Here is the full list.

The Wegovy pill led to 13.6% weight loss vs 14.9% for the Wegovy shot in separate trials. See how GLP-1 pills compare with injections and how to take them.

No trial has tested GLP-1 microdosing. Low doses cause some loss (6.0% vs 13.8% in a semaglutide trial), but labels call starter doses initiation only.

GLP-1 drugs aren't approved in pregnancy. Wegovy and Ozempic labels say stop 2 months before trying to conceive. What studies show on fertility and birth defects.

Wegovy's label reports hair loss in 3.3% of adults versus 1% on placebo. Here is why rapid weight loss triggers it, and how long regrowth really takes.

Not before December 2031 on current patents. The FDA Orange Book lists the core semaglutide patent to Dec 5, 2031, and Novo Nordisk puts US expiry at 2032.

Missed a GLP-1 dose? FDA labels allow a late Ozempic shot within 5 days and Mounjaro or Zepbound within 4 days. Here are the rules for every GLP-1 drug.

No. An FDA review of 91 trials and 2.2 million patients found no added suicide risk, and in 2026 the warning came off Wegovy and Zepbound labels.

GLP-1 drugs are not FDA-approved for type 1 diabetes. Trials show 5 to 9 kg weight loss but more lows and ketosis. The ADA 2026 now lists them for obesity.

No FDA label gives switching steps. Tirzepatide labels start everyone at 2.5 mg weekly, then rise by 2.5 mg after at least 4 weeks. What the evidence shows.

No FDA label lists loose skin for Wegovy or Zepbound. The cause is the 15% to 21% weight loss in trials. See the evidence and when surgeons operate.

Burping affects up to 7% of adults on Wegovy vs under 1% on placebo. Why GLP-1 drugs cause sulfur burps, what is unproven, and the steps NIDDK supports.

Tirzepatide cut birth control pill peak hormone levels by 55% to 66% after one dose. See what each GLP-1 label says about oral contraceptives and warfarin.

Zepbound is the only GLP-1 class drug FDA-approved for sleep apnea. In trials, breathing events fell by 25 to 29 per hour. What it means for CPAP and stopping.